Potentially serious Lamotrigine-related skin rash

Area of Science:

• Pediatric Neurology
• Dermatology
• Clinical Pharmacology

Background:

• Lamotrigine (LTG) is an antiepileptic drug known for its efficacy.
• Skin rash is a recognized adverse effect of LTG.
• The incidence and severity of LTG-related rash in pediatric epilepsy populations require further characterization.

Purpose of the Study:

• To document the occurrence and clinical spectrum of lamotrigine-associated skin rashes in children with epilepsy.
• To identify risk factors and outcomes associated with LTG-induced dermatologic adverse events.

Main Methods:

• Prospective cohort study of children with epilepsy treated with LTG over a 5-year period.
• Data collection included patient demographics, LTG dosage, concomitant medications (especially valproic acid - VPA), and rash characteristics.
• Clinical outcomes, including rash severity and treatment, were systematically recorded.

Main Results:

• Out of 207 children treated with LTG, 15 (7.2%) developed skin rash.
• Rash severity varied, with 7 children experiencing mild rash and 8 experiencing severe reactions requiring hospitalization.
• Five children (2.4%) were diagnosed with Stevens-Johnson syndrome, including one case that progressed to toxic epidermal necrolysis and resulted in mortality.
• Concomitant VPA use was noted in the majority of severe rash cases (7/8).

Conclusions:

• Lamotrigine-related skin rash is a significant adverse event in pediatric epilepsy, with a notable incidence of severe reactions.
• The risk of severe rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis, necessitates vigilant monitoring.
• The combination of LTG with valproic acid may increase the risk of severe dermatologic adverse events in children.